South Korea Won’t Extend Stockpiled Tamiflu Expiration Dates
This article was originally published in PharmAsia News
MFDS rejects Korea Centers for Disease Control and Prevention bid to retain expiring Tamiflu stockpile. South Korea would need to replace expiring supplies to maintain same levels of stockpile.
You may also be interested in...
SEOUL - Hoping to avoid a recurrence of the influenza A/H1N1 pandemic from a year ago, South Korea's Ministry of Health and Welfare called on the country's senior citizens and the underprivileged to get free-of-charge flu vaccines beginning early October
Green Cross Obtains South Korean Approval For Peramivir During Drive To Secure More Anti-Influenza Medicines Beyond Roche and GSK Products
SEOUL - South Korea's Green Cross has obtained approval from South Korea's FDA to sell the injectable antiviral drug Rapiacta (peramivir), developed by BioCryst Pharmaceuticals in the U.S., during a government drive to make more flu-fighting medicines available beyond Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir)
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.